61 results on '"Neuschwander-Tetri, Brent A"'
Search Results
2. Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD
3. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
4. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
5. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
6. Ube4A maintains metabolic homeostasis and facilitates insulin signaling in vivo
7. A global research priority agenda to advance public health responses to fatty liver disease
8. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
9. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease
10. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
11. Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
12. Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis
13. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
14. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
15. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
16. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis
17. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis
18. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children
19. New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile
20. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
21. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice
22. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
23. Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease
24. Differences in the Degree of Cerulein-Induced Chronic Pancreatitis in C57BL/6 Mouse Substrains Lead to New Insights in Identification of Potential Risk Factors in the Development of Chronic Pancreatitis
25. FRI-208 qBallooning: AI-based ballooned hepatocyte detection and quantification by second harmonic generation/two photon excitation microscopy
26. FRI-222-YI A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
27. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
28. Lifestyle Modification as the Primary Treatment of NASH
29. Sa1546 INCREASED LIVER FIBROSIS IS THE KEY CLINICAL FACTOR ASSOCIATED WITH INCREASED FUTURE SEVERE LIVER DISEASE OUTCOMES IN A PROSPECTIVE COHORT OF ADULTS WITH ALPHA-1-ANTITRYPSIN DEFICIENCY
30. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
31. Pharmacologic management of nonalcoholic fatty liver disease
32. Chapter 9 - Fatty Liver and Nonalcoholic Steatohepatitis
33. Abstract #1177547: Sex hormone binding globulin (SHBG) is a marker of liver fibrosis in men with nonalcoholic fatty liver disease (NAFLD)
34. Concurrence of Histologic Features of Steatohepatitis with Other Forms of Chronic Liver Disease
35. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis
36. Fatty liver and nonalcoholic steatohepatitis
37. Repetitive Acute Pancreatic Injury in the Mouse Induces Procollagen α1(I) Expression Colocalized to Pancreatic Stellate Cells
38. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
39. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
40. Contributors
41. Chapter 7 - Fatty liver and nonalcoholic steatohepatitis
42. Mo1460 - Apolipoprotein (apo)A-V Deficiency Enhances Hepatic Synthesis of Ceramide, a Major Fatty Acid Metabolite, Triggering a Progression from Simple Steatosis to Nonalcoholic Steatohepatitis (NASH) in Chow-Fed apoA-V KO Mice
43. 397 - Inappropriate Acute Hepatitis Testing: When a One-Step Intervention is not Enough
44. 826 Adeno-Associated-Virus 2/8 (AAV)-Mediated Gene Transfer of the Human Apolipoprotein (APO) A-V Confers Protection Against Liver Steatosis in APOA-V Knockout (KO) Mice
45. Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply
46. Contributors
47. Retinoid X receptor: the forgotten partner in regulating lipid metabolism?
48. More evidence that probiotics may have a role in treating fatty liver disease
49. 977 The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C
50. 730 NASH: clinical assessment of 501 patients from two separate academic medical centers with validation of a clinical scoring system for advanced hepatic fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.